Clinical value of protein S100 and melanoma-inhibitory activity (MIA) in malignant melanoma

被引：12

作者：

Tas, F ^{[1
]}

Yasasever, V ^{[1
]}

Duranyildiz, D ^{[1
]}

Camlica, H ^{[1
]}

Ustuner, Z ^{[1
]}

Aydiner, A ^{[1
]}

Topuz, E ^{[1
]}

机构：

[1] Univ Istanbul, Onkol Enstitusu, TR-34390 Istanbul, Turkey

来源：

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 2004年 / 27卷 / 03期

关键词：

melanoma; melanoma-inhibitory protein (MIA); S100;

D O I：

10.1097/01.COC.0000054895.39558.DB

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Serum protein S100 and melanoma-inhibitory protein (MIA) have been described as useful tumor markers for malignant melanoma. In this study, these two serum proteins were compared in 48 patients with melanoma at different stages of disease. Serum concentrations of S 100 and MIA were measured by immunoradiometric and enzyme-linked immunosorbent assays, respectively. We found that the cut-off values were 17.4 ng/ml for MIA and 0.09 mug/l for S100. Five patients had stage I-II, 22 had stage III, and 21 had stage IV disease. Serum levels of two markers were elevated with metastatic disease (p < 0.05). Sensitivities of the MIA were found higher compared with S100 in patients with extensive (M1c) metastatic disease and with chemotherapy nonresponders (p > 0.05). We showed a trend for worsened outcome in patients with elevated MIA level in univariate analysis. MIA was found to be more sensitive and is a potential prognostic marker for patients with metastatic malignant melanoma in comparison with S100.

引用

页码：225 / 228

页数：4

共 20 条

[11]

Hauschild A, 1999, BRIT J DERMATOL, V140, P1065

[12] Prognostic significance of serum S100B detection compared with routine blood parameters in advanced metastatic melanoma patients [J].

Hauschild, A ;

Michaelsen, J ;

Brenner, W ;

Gläser, R ;

Henze, E ;

Christophers, E .

MELANOMA RESEARCH, 1999, 9 (02) :155-161

[13] Comparison of two prognostic markers for malignant melanoma:: MIA and S100 β [J].

Juergensen, A ;

Holzapfel, U ;

Hein, R ;

Stolz, W ;

Buettner, R ;

Bosserhoff, AK .

TUMOR BIOLOGY, 2001, 22 (01) :54-58

[14]

MARTENSON ED, 1999, 3 INT C ADJ THER MAL

[15] Evaluation of new putative tumor markers for melanoma [J].

Miliotes, G ;

Lyman, GH ;

Cruse, CW ;

Puleo, C ;

Albertini, J ;

Rapaport, D ;

Glass, F ;

Fenske, N ;

Soriano, T ;

Cuny, C ;

VanVoorhis, N ;

Reintgen, D .

ANNALS OF SURGICAL ONCOLOGY, 1996, 3 (06) :558-563

[16]

MUHBAUER M, 1999, CLIN CANCER RES, V5, P1099

[17]

Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/0968-0004(96)10020-7

[18]

Schmitz C, 2000, ANTICANCER RES, V20, P5059

[19]

Schultz ES, 1998, BRIT J DERMATOL, V138, P426

[20] Prognostic value of serum analyses of S-100 beta protein in malignant melanoma [J].

vonSchoultz, E ;

Hansson, LO ;

Djureen, E ;

Hansson, J ;

Karnell, A ;

Nilsson, B ;

Stigbrand, T ;

Ringborg, U .

MELANOMA RESEARCH, 1996, 6 (02) :133-137

← 1 2 →